However, the efficacy of these immunotherapies is restricted to only a subset of patients who have high level of CD8+ T cell infiltration (18–20), and strategies enhancing tumor-specific CD8+ T cell abundance show improved tumor suppression (21, 22). This evidence concerns the gene CD8A and neoplasm.